News
and updates
News
and updatesDolutegravir for Children living with HIV
Picturing Health have developed a short video explaining how dolutegravir, using preliminary data from the ODYSSEY trial, has gained approval for use in children.
ODYSSEY trial plays an important role in the FDA approval of dolutegravir for children – a big step towards timely access to optimal ART for children.
Data from the ongoing P1093 and ODYSSEY (PENTA20) studies have led to the successful approval of ViiV Healthcare’s submission to the U.S. FDA of the adult formulation for children weighing ≥20kg and dolutegravir dispersible tablets for children of 4 weeks of age and older.
What does COVID-19 mean for those living in HIV communities?
New videos have been developed by Picturing Health, to inform and promote behaviour that can reduce the spread of Coronavirus in Africa and South Asia
ODYSSEY trial: COVID-19 response and CROI update
Odyssey trial’s COVID-19 response and CROI update
ODYSSEY to be presented at CROI 2020
Results from the Odyssey trial will be presented at this year’s Conference on Retroviruses and Opportunistic Infections in Boston, USA.
Data from ODYSSEY are used by ViiV Healthcare to file FDA and EMA submissions for the first-ever dispersible formulation of dolutegravir for children living with HIV
Using data from the ongoing P1093 and the ODYSSEY (PENTA20) study, ViiV Healthcare has filed submissions to the FDA and EMA for the first-ever dispersible formulation of dolutegravir (DTG) for children living with HIV. If approved, this new formulation of dolutegravir...
Recruitment to the main trial is complete!
ODYSSEY has reached a major milestone by completing the recruitment of participants to the main trial. A big thank you to all the sites and everyone else for their hard work and continuous effort put into making the study a success.
ODYSSEY presented at ‘Annual Conference of the International Society for Clinical Biostatistics’ in Leuven, Belgium
We are pleased to report that a presentation from the ODYSSEY team at MRC CTU at UCL was well received at the 40th Annual Conference of the International Society for Clinical Biostatistics in Leuven, Belgium (14 – 18 July 2019). Rebecca Turner delivered the talk as part of the Bayesian clinical trials session on Tuesday morning (16 July).
IAS 2019 – Oral abstract on ODYSSEY PK study presented at conference in Mexico City
We are delighted to report that a late breaker oral presentation on the key PK substudy nested within the ODYSSEY trial was accepted and presented at the 10th IAS Conference on HIV Science (IAS 2019) on 21-24 July, 2019.
Adult dolutegravir could offer a practical and accessible treatment for children living with HIV
Adult doses of an antiviral drug could offer a practical and accessible option for children weighing 20-25kg living with HIV. The results of the pharmacokinetic sub-study (measuring levels of drug in the blood to check if doses are correct), part of the ODYSSEY trial, were presented at the Conference on Retroviruses and Opportunistic Infections, in Seattle, Washington.